Assessing combined effects of varenicline and N‐acetylcysteine on reducing nicotine seeking in rats
- 22 February 2022
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 27 (2) , e13151
Abstract
Nicotine addiction is a chronic relapsing brain disorder, and cigarette smoking is the leading cause of preventable death in the United States. Currently, the most effective pharmacotherapy for smoking cessation is Varenicline (VRN), which reduces both positive and negative reinforcement by nicotine. Clinically, VRN attenuates withdrawal symptoms and promotes abstinence, but >50% of smokers relapse within 3 months following a quit attempt. This may indicate that VRN fails to ameliorate components of nicotine‐induced neuroplasticity that promote relapse vulnerability. Animal models reveal that glutamate dysregulation in the nucleus accumbens is associated with nicotine relapse. N‐acetylcysteine (NAC) normalizes glutamate transmission and prolongs cocaine abstinence. Thus, combining VRN and NAC may promote and maintain, respectively, nicotine abstinence. In rats, we found that VRN effectively reduced nicotine self‐administration and seeking in early abstinence, but not seeking later in abstinence. In contrast, NAC reduced seeking only later in abstinence. Because VRN and NAC are sometimes associated with mild adverse effects, we also evaluated a sequential approach combining subthreshold doses of VRN during self‐administration and early abstinence with subthreshold doses of NAC during late abstinence. As expected, subthreshold VRN did not reduce nicotine intake. However, subthreshold VRN and NAC reduced seeking in late abstinence, suggesting a combined effect. Overall, our results suggest that combining subthreshold VRN and NAC is a viable and drug‐specific approach to promote abstinence and reduce relapse while minimizing adverse effects. Our data also suggest that different components and time points in addiction engage the different neurocircuits targeted by VRN and NAC.Keywords
Funding Information
- National Institute on Drug Abuse (DA003906, DA012513, DA038700, DA046373, DA047426, DA047426‐01A1)
- U.S. Department of Veterans Affairs (BX004727)
- National Science Foundation (OIA‐1539034)
This publication has 56 references indexed in Scilit:
- Reinstatement of nicotine seeking is mediated by glutamatergic plasticityProceedings of the National Academy of Sciences, 2013
- Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in micePsychopharmacology, 2013
- Suicidal Behavior and Depression in Smoking Cessation TreatmentsPLOS ONE, 2011
- New medications for drug addiction hiding in glutamatergic neuroplasticityMolecular Psychiatry, 2011
- Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response controlPsychopharmacology, 2011
- Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineDrug Safety, 2010
- Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine SeekingBiological Psychiatry, 2010
- Neurocircuitry of AddictionNeuropsychopharmacology, 2009
- The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and HumansBiological Psychiatry, 2009
- Association of Nicotine Addiction and Nicotine's Actions With Separate Cingulate Cortex Functional CircuitsArchives of General Psychiatry, 2009